Clinical research company Fortrea Holdings (NASDAQ:FTRE) missed Wall Street’s revenue expectations in Q4 CY2024, with sales ...

Fortrea (NASDAQ:FTRE – Get Free Report) had its price objective lowered by investment analysts at Barclays from $25.00 to $12 ...

Fortrea (NASDAQ:FTRE – Get Free Report) had its target price decreased by analysts at The Goldman Sachs Group from $22.00 to ...

Project Optimus seeks to transform how doses are selected and optimised in oncology drug development. As this initiative ...

Q4 2024 Earnings Call Transcript March 3, 2025 Fortrea Holdings Inc. misses on earnings expectations. Reported EPS is $0.18 ...

Ladies and gentlemen, thank you for standing by, and welcome to Fortrea fourth-quarter 2024 earnings conference call. (Operator Instructions) Please be advised that today's conference is being ...

BofA lowered the firm’s price target on Fortrea (FTRE) to $10 from $17 and keeps an Underperform rating on the shares after a Q4 miss and FY25 ...

Barclays lowered the firm’s price target on Fortrea (FTRE) to $12 from $25 and keeps an Equal Weight rating on the shares.Discover the Best ...

A Durham company with a slumping stock is implementing changes to its board after reaching a deal with an activist investor.

Shares of Fortrea Holdings sank to a new low after the company said it expects revenue to drop this year. The stock fell 31% to a new all-time low of $9.55 in the first half of the trading day. The ...

Fortrea is a global, late-stage contract research organization, or CRO, that provides comprehensive Phase I through IV clinical trial management, clinical pharmacology, and patient access solutions.